Printer Friendly

ALPHA 1 BIOMEDICALS, INC. ANNOUNCES PUBLICATION OF PRICE APPROVAL OF THYMOSIN ALPHA 1 IN ITALY

 BETHESDA, Md., April 16 /PRNewswire/ -- Alpha 1 Biomedicals, Inc. (NASDAQ: ALBM) announced today that the Italian Government has published the official price for Thymosin alpha 1 in the Gazzetta Ufficiale, a newspaper of the Italian Government. The price is 169,650 lire, for two milligrams. At the current exchange rate for the Italian Lira to the U.S. dollar, this puts the price of the 52 dose, six-month regimen at $5,500 to $6,000.
 Vincent F. Simmon, Ph.D., president and CEO of Alpha 1 stated "We are extremely pleased that the price has finally been announced and is very favorable. This sets an excellent precedent for pricing of Thymosin in other countries and will have a beneficial effect on Alpha 1's royalty returns. Approval for marketing of Thymosin alpha 1 in Italy is expected within the next few months."
 The company previously stated that its Italian licensee, Sclavo S.p.A (Siena, Italy) had received preliminary approval for Thymosin alpha 1 from the Italian Ministry of Health for the treatment of primary immunodeficiencies and as an adjuvant for influenza vaccine in renal dialysis patients. Patient populations for these two indications are small and therefore, initial sales of Thymosin alpha 1 are expected to be modest. However, Sclavo sponsored clinical trails in Italy are in progress using Thymosin for the treatment of chronic hepatitis B and C, cancer and AIDS. A five center trial in Italy using Thymosin alpha 1 for the treatment of chronic hepatitis B is expected to be completed during the summer of 1993. If the trial is successful, the approval for chronic hepatitis B indication could occur by mid-1994 in Italy, according to Sclavo.
 In anticipation of marketing approval, the company announced earlier this year that Sclavo will build, at Sclavo's expense, a Thymosin alpha 1 manufacturing facility using manufacturing technology developed by Alpha 1. Both companies will share equally in the manufacturing profits. The facility could be operational by the end of 1994.
 Thymosin alpha 1 is currently in an Alpha 1-sponsored multi-center Phase III trial for the treatment of chronic hepatitis B in the U.S. Alpha 1 is also sponsoring U.S. clinical trials with Thymosin alpha 1 with other drugs for the treatment of chronic active hepatitis C and AIDS.
 -0- 4/16/93
 /CONTACT: Vincent F. Simmon, Ph.D., president and CEO of Alpha 1 Biomedicals, Inc., 301-564-4400; or Anita Monteith-Dixon of Long Ridge Associates, 203-790-0647, for Alpha 1/
 (ALBM)


CO: Alpha 1 Biomedicals, Inc. ST: Maryland IN: MTC SU:

WB-LR -- NY020 -- 6665 04/16/93 10:30 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 16, 1993
Words:429
Previous Article:KRAFT GENERAL FOODS EUROPE PRESIDENT TO RETIRE
Next Article:DRS COMPLETES REFINANCING OF CREDIT FACILITY OF SUBSIDIARY
Topics:


Related Articles
ALPHA 1 BIOMEDICALS, INC. REPORTS THIRD QUARTER CALENDAR YEAR 1992 RESULTS
U.S. TESTS OF POTENTIAL AIDS VACCINE CONFIRM EARLIER U.K. TESTS
SCHERING-PLOUGH LICENSES FROM SCICLONE POTENTIAL HEPATITIS TREATMENT IN JAPAN
ALPHA 1 BIOMEDICALS ANNOUNCES REVISIONS TO TERMS OF THE REDEMPTION OF ITS CLASS B WARRANTS
ALPHA 1 BIOMEDICALS INC. ANNOUNCES MANUFACTURING EXPANSION
ALPHA 1 BIOMEDICALS, INC. FOURTH QUARTER AND CALENDAR YEAR 1992 RESULTS
ENROLLMENT COMPLETED IN ALPHA 1 BIOMEDICALS' PHASE III CLINICAL TRIAL
UPDATE ON HGP-30 AIDS VACCINE PRESENTED AT BERLIN AIDS CONFERENCE
ALPHA 1 BIOMEDICALS, INC. APPOINTS SUZANNE K. BECKNER AS DIRECTOR OF DEVELOPMENT
THYMOSIN ALPHA 1 COMBINATION STUDY SUGGESTS CD4+ RESPONSE

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters